Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers an… Read more
Crescita Therapeutics Inc (CRRTF) - Total Assets
Latest total assets as of September 2025: $21.46 Million USD
Based on the latest financial reports, Crescita Therapeutics Inc (CRRTF) holds total assets worth $21.46 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Crescita Therapeutics Inc - Total Assets Trend (2014–2024)
This chart illustrates how Crescita Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Crescita Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Crescita Therapeutics Inc's total assets of $21.46 Million consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.6% |
| Accounts Receivable | $1.58 Million | 7.3% |
| Inventory | $4.05 Million | 18.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.74 Million | 8.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Crescita Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crescita Therapeutics Inc's current assets represent 70.3% of total assets in 2024, a decrease from 94.5% in 2014.
- Cash Position: Cash and equivalents constituted 42.6% of total assets in 2024, up from 27.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 18.6% of total assets.
Crescita Therapeutics Inc Competitors by Total Assets
Key competitors of Crescita Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Crescita Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Crescita Therapeutics Inc generates 0.90x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Crescita Therapeutics Inc is currently not profitable relative to its asset base.
Crescita Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.12 | 2.70 | 4.20 |
| Quick Ratio | 2.07 | 1.68 | 3.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.86 Million | $ 10.25 Million | $ 14.78 Million |
Crescita Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Crescita Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -11.5% |
| Total Assets | $21.78 Million |
| Market Capitalization | $6.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Crescita Therapeutics Inc's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Crescita Therapeutics Inc's assets decreased by 11.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Crescita Therapeutics Inc (2014–2024)
The table below shows the annual total assets of Crescita Therapeutics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $21.78 Million | -11.47% |
| 2023-12-31 | $24.60 Million | -13.64% |
| 2022-12-31 | $28.48 Million | -1.52% |
| 2021-12-31 | $28.92 Million | +7.80% |
| 2020-12-31 | $26.83 Million | -0.02% |
| 2019-12-31 | $26.84 Million | -2.64% |
| 2018-12-31 | $27.57 Million | +22.16% |
| 2017-12-31 | $22.57 Million | -47.55% |
| 2016-12-31 | $43.02 Million | +3521.04% |
| 2015-12-31 | $1.19 Million | -27.38% |
| 2014-12-31 | $1.64 Million | -- |